ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children

C. A. Felix, M. R. Hosler, N. J. Winick, M. Masterson, A. E. Wilson, B. J. Lange

Research output: Contribution to journalArticlepeer-review

128 Scopus citations


We examined clinical, morphologic, and cytogenetic feature and ALL-1 (MLL, HtrxI, HRX) gene rearrangements in 17 cases of secondary leukemia that occurred 11 months to 9 years from diagnoses of primary cancers in children who received topoisomerase II inhibitors or developed secondary leukemias typical of those associated with this therapy. Primary diagnoses included nine solid tumors and eight leukemias. Ten secondary leukemias were acute myeloid leukemia (AML), one was of mixed lineage, two were acute lymphoblastic leukemia (ALL), and four presented as myelodysplasia. Of 15 cases with 11q23 involvement, 11 (73%) were cytogenetically identifiable; four cases had molecular rearrangement only. By Southern blot, rearrangements within the ALL-1 gene were similar to sporadic cases. The results of this analysis suggest the following: (1) In most pediatric cases of topoisomerase II inhibitor-associated leukemia, there is disruption of the breakpoint cluster region of the ALL-1 gene at chromosomal band 11q23. (2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was dactinomycin in one case, and, in another case, no topoisomerase II inhibitor was administered. (3) There is clinical, morphologic, cytogenetic, and molecular heterogeneity in pediatric secondary 11q23 leukemia. (4) There are some survivors of pediatric secondary 11q23 leukemia, but the outcome is most often fatal.

Original languageEnglish (US)
Pages (from-to)3250-3256
Number of pages7
Issue number11
StatePublished - Jun 1 1995

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children'. Together they form a unique fingerprint.

Cite this